Dermatophytosis — chiefly tinea corporis and tinea cruris — surges in late June because monsoon humidity above 80 percent and persistent skin moisture create ideal conditions for dermatophyte fungi to colonise the keratin layer. Evidence-based prevention centres on keeping skin dry, wearing breathable fabrics, and avoiding over-the-counter steroid-antifungal combination creams that the IADVL's 2018 and 2022 consensus statements identify as a primary driver of India's drug-resistant fungal-infection crisis.

The Monsoon Paradox: Why Your Skin Pays the Price for the Rain You Prayed For

Here is the paradox most Indians live but rarely name: the rains that the whole subcontinent prays for also wage a quiet, itchy war on the very skin you stand in. Within days of the first proper downpour — sometimes within hours of a commute through waterlogged streets — consulting rooms in dermatology departments from Mumbai to Kolkata begin filling with patients scratching at angry red rings on their torsos and raw, stinging patches in their groin folds. Dermatophytosis is not new, not exotic, and not complicated. It is, however, getting harder to treat every single year. And the reason for that is not the fungus — it is us.

According to the Indian Journal of Dermatology, Venereology and Leprology (IJDVL), dermatophyte infections account for a significant share of all outpatient dermatology visits during the monsoon months, with tinea corporis — the classic ringworm of the body — and tinea cruris — the groin variant colloquially called jock itch — together representing the dominant clinical presentations. Published seasonal analyses from tertiary centres in India document a clear and reproducible spike beginning in late June, tracking almost exactly with the rise in relative humidity past the 80-percent mark. The numbers are stark: some hospital-based studies report a two- to threefold increase in new dermatophytosis cases between June and September compared with the dry winter months.

India Herald's Vantage: This Is Not a Weather Problem — It Is a Self-Inflicted Resistance Crisis

The raw count, however, does not tell the real story. The dimension that most monsoon-health guides miss — and the spine India Herald's read of this annual crisis runs along — is that the Indian dermatophytosis epidemic of the 2020s is no longer a simple seasonal nuisance. It is an accelerating, partly iatrogenic crisis, driven less by the weather and more by a single behavioural pattern: the mass self-medication of fungal rashes with over-the-counter steroid-antifungal-antibacterial combination creams.

Dermatologists across India have raised the alarm for years. The IADVL's 2018 consensus statement (published in the Indian Dermatology Online Journal) and its updated 2022 task-force recommendations explicitly identified irrational use of topical steroid-antifungal combination products as a primary driver of what the task force termed India's "chronic, recurrent, and recalcitrant dermatophytosis" epidemic — a phenomenon the IADVL noted was rarely seen at this scale anywhere else in the world. Published data from the IJDVL and studies cited in the Journal of the American Academy of Dermatology have documented that Trichophyton mentagrophytes and Trichophyton rubrum, the species most responsible for tinea corporis and tinea cruris in India, are showing worrying levels of resistance to first-line antifungals, as reported by multiple Indian tertiary-care centres.

The mechanism, as described in the IADVL consensus, is straightforward: the steroid component in these combination creams suppresses visible inflammation (and thus the itch), giving patients the illusion of a cure while the fungus reportedly continues to spread beneath quieter skin. When the steroid is stopped, the rash returns — often worse, often wider, and often resistant to agents that would have cleared it a decade ago, according to clinical observations documented in the dermatology literature.

Industry and regulatory note: India Herald reached out to the Central Drugs Standard Control Organisation (CDSCO) and representatives of the Indian pharmaceutical trade body for comment on the IADVL's call for prescription-only reclassification of steroid-antifungal combination products. As of publication on 26 June 2025, no response had been received. This article will be updated if and when a response is provided. India Herald notes that these products remain legally available over the counter as of the date of publication; the safety concerns cited here are attributed to the IADVL's published task-force recommendations and peer-reviewed dermatology literature, not to India Herald's independent assessment.

What the Evidence Actually Supports for Prevention

So what does the evidence actually support for prevention — the kind of advice that holds up under scrutiny, not the vague "stay dry" counsel that fills wellness listicles every June?

1. Keep skin genuinely dry, not just towelled-off. Dermatophytes need moisture to colonise. According to published dermatology guidelines, the critical step is reducing the duration of skin wetness — changing out of damp clothing promptly after rain exposure, using absorbent cotton undergarments, and applying a plain antifungal dusting powder (not a steroid cream) to skin folds prone to maceration: the groin, under the breasts, between the toes. A study cited in the Indian Journal of Medical Research notes that occlusive synthetic fabrics significantly raise local skin humidity, making fabric choice a modifiable risk factor during monsoon months.

2. Do not share towels, clothing, or bedding during active infection. Dermatophyte transmission via fomites — contaminated fabrics and surfaces — is well-documented. Washing towels and undergarments in hot water and drying them thoroughly (a challenge in monsoon weather, and one reason infections persist) reduces fungal load. According to the WHO's guidance on superficial mycoses, direct skin-to-skin contact and shared personal items remain primary transmission routes.

3. Stop the steroid-combination cream — consult a dermatologist instead. This is, per the IADVL 2018 and 2022 consensus statements, the single most impactful behavioural change an Indian household can make. If a rash appears — the red, ring-shaped, scaly, itchy lesion characteristic of tinea corporis, or the symmetric groin-fold rash of tinea cruris — the evidence-based response is to consult a dermatologist, not to reach for an over-the-counter combination cream. The IADVL consensus is unambiguous: topical antifungals alone (the specific agents to be chosen by the treating dermatologist based on clinical assessment) are the recommended first line for limited disease. For widespread or recurrent cases, oral antifungals under medical supervision are advised. The IADVL consensus explicitly states that the steroid component is contraindicated in routine dermatophytosis management. India Herald does not recommend specific drug names or self-treatment regimens; all treatment decisions should be made by a qualified dermatologist.

4. Complete the full course — do not stop when itching stops. One of the quieter drivers of resistance, according to the IADVL 2022 task-force document, is premature discontinuation of antifungal therapy once itching resolves. The fungus is often still viable in the keratin layer when symptoms subside. The IADVL task force recommends continuing topical treatment for at least one to two weeks after clinical clearance, and completing the full oral course as prescribed by the treating dermatologist for the duration the clinician determines appropriate based on severity and response. Patients should not self-adjust duration.

The Forward Read: What to Watch in 2025 and Beyond

If the current trajectory holds — unchecked combination-cream sales, growing antifungal-resistance signals in published laboratory data, and no national prescription-enforcement mechanism for these products — India Herald's assessment is that dermatologists will see not just seasonal surges but a rising baseline of chronic, difficult-to-treat fungal infections that persists year-round, monsoon or not. The IADVL has petitioned drug regulators for reclassification; whether the monsoon of 2025–26 is the one that finally forces regulatory action or simply adds another chapter to the crisis will depend on how quickly the message reaches the neighbourhood pharmacy counter.

Watch for any movement from the Central Drugs Standard Control Organisation (CDSCO) on reclassifying steroid-antifungal combinations as prescription-only — that single regulatory step, the IADVL task force has argued in its published recommendations, would do more to curb the epidemic than any number of awareness campaigns. As noted above, CDSCO had not responded to India Herald's query as of publication.

The rain will not stop. The humidity will not relent. But the fungus thriving on your skin this monsoon is, in a very real sense, a problem India chose — one tube of combination cream at a time. The question is whether this is the year the country finally stops choosing it.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. All treatment decisions — including choice of medication, dosage, and duration — should be made in consultation with a qualified dermatologist. India Herald's reporting is based on published peer-reviewed literature and expert-body consensus statements as cited. No specific commercial product or brand is named or targeted.

Key Takeaways

• Dermatophytosis (tinea corporis and tinea cruris) cases spike two- to threefold during India's monsoon, driven by sustained humidity above 80 percent, according to hospital-based studies published in Indian dermatology journals.
• The IADVL's 2018 and 2022 consensus statements identify mass self-medication with over-the-counter steroid-antifungal combination creams as a primary driver of India's rising antifungal-resistant dermatophytosis — a crisis the task force says is largely unique to India at this scale.
• Evidence-based prevention rests on keeping skin dry, wearing breathable cotton, avoiding shared personal fabrics, using plain antifungal powder in skin folds, and — critically — never applying steroid-containing combination creams without a dermatologist's prescription, per IADVL guidelines.
• Premature discontinuation of antifungal treatment when itching stops, rather than completing the full course as prescribed by a dermatologist, contributes to resistant infections, per the IADVL 2022 task-force recommendations.
• Regulatory reclassification of steroid-antifungal combinations as prescription-only remains the single most impactful systemic intervention, according to the IADVL task force. CDSCO had not responded to India Herald's query as of 26 June 2025.

Frequently Asked Questions

Why do fungal skin infections increase during the Indian monsoon?

Sustained relative humidity above 80 percent and persistent skin moisture from rain and sweat create optimal conditions for dermatophyte fungi (Trichophyton species) to colonise the skin's keratin layer, leading to infections like tinea corporis and tinea cruris, according to seasonal data published in Indian dermatology journals.

What is the difference between tinea corporis and tinea cruris?

Tinea corporis is a dermatophyte infection of the body presenting as ring-shaped, scaly, itchy lesions; tinea cruris affects the groin folds with symmetric, red, scaly plaques. Both are caused by the same group of fungi and share similar treatment protocols, according to standard dermatology textbooks.

Why are steroid-antifungal combination creams considered problematic for fungal infections?

According to the IADVL's 2018 and 2022 consensus statements, the steroid component suppresses visible inflammation and itch, reportedly masking the infection while the fungus continues to spread. The IADVL says this pattern leads to recurrence, wider spread, and growing antifungal resistance. India Herald notes that CDSCO had not responded to queries on this topic as of 26 June 2025.

How long should antifungal treatment be continued after symptoms resolve?

The IADVL 2022 task-force recommendations advise continuing topical antifungal application for at least one to two weeks after clinical clearance. For oral antifungal courses in recalcitrant cases, the task force recommends completing the full duration as prescribed by the treating dermatologist. Patients should not self-adjust treatment length.

How can I prevent monsoon fungal skin infections?

Per IADVL guidelines and published dermatology literature: keep skin dry by changing damp clothing promptly, wear breathable cotton fabrics, apply plain antifungal dusting powder to sweat-prone folds, avoid sharing towels and undergarments, and never use steroid-containing combination creams without a dermatologist's prescription. All treatment decisions should be made by a qualified dermatologist.